2-Piperidinioethansulfonat | 4706-21-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-Piperidinioethansulfonat
• 英文别名: 2-piperidinylethanesulfonic acid；2-Piperidin-1-ium-1-ylethanesulfonate；2-piperidin-1-ium-1-ylethanesulfonate
• CAS: 4706-21-2
• 化学式: C₇H₁₅NO₃S
• 分子量: 193.267
• InChiKey: XARBMSAAZHEXEK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.3
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  66
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-(2-氯乙基)哌啶盐酸盐 在 sodium sulfite 、 盐酸 作用下， 以 水 为溶剂， 反应 0.67h， 以73%的产率得到2-Piperidinioethansulfonat
  参考文献：
  名称：

  Methods and compositions for treating amyloid-related diseases

  摘要：

  描述了用于治疗或预防与淀粉样蛋白相关疾病的方法、化合物、药物组合物和试剂盒。

  公开号：

  US20060223855A1

文献信息

• Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
  申请人：Sun Li Connie

  公开号：US20050009832A1

  公开（公告）日：2005-01-13

  The present invention relates to 8-amino-aryl-substituted imidazopyrazines which modulate the activity of protein kinases (“PKs”). The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

  本发明涉及8-氨基-芳基取代的咪唑并吡嗪类化合物，这些化合物能够调节蛋白激酶（“PKs”）的活性。因此，本发明的化合物可用于治疗与异常PK活性相关的疾病。本发明还公开了包含这些化合物的药物组合物、使用包含这些化合物的药物组合物治疗疾病的方法以及它们的制备方法。
• Process for production of delta-9- tetrahydrocannabinol
  申请人：Burdick C. David

  公开号：US20070093665A1

  公开（公告）日：2007-04-26

  The present invention relates to a process for preparation of a delta-9-tetrahydrocannabinol compound or derivative thereof involving treating a first intermediate compound with an organoaluminum-based Lewis acid catalyst, under conditions effective to produce the delta-9-tetrahydrocannabinol compound or derivative thereof. Another aspect of the present invention relates to a process for preparation of a cannabidiol or cannabidiolate compound involving reacting a first starting compound with a second starting compound in the presence of a metal triflate catalyst, under conditions effective to form the cannabidiol or cannabidiolate compound. The present invention also relates to a compound of the formula: where R 8 , R 9 , and R 10 are the same or different and independently selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or halo, with R 1 , R 2 , and R 3 defined herein.

  本发明涉及一种制备Δ-9-四氢大麻酚化合物或其衍生物的方法，涉及将第一中间化合物与基于有机铝的Lewis酸催化剂处理，在有效条件下产生Δ-9-四氢大麻酚化合物或其衍生物。本发明的另一个方面涉及一种制备大麻二酚或大麻二酚盐化合物的方法，涉及在金属三氟甲磺酸盐催化剂存在下，将第一起始化合物与第二起始化合物反应，在有效条件下形成大麻二酚或大麻二酚盐化合物。本发明还涉及一个化合物，其化学式为：其中R8、R9和R10相同或不同，并且独立地选自H、取代或未取代的烷基、取代或未取代的芳基、取代或未取代的杂环芳基或卤素，其中R1、R2和R3在此定义。
• [EN] CARBOXAMIDE DERIVATIVES OF PYRROLIDINE, PIPERIDINE AND HEXAHYDROAZEPINE FOR THE TREATMENT OF THROMBOSIS DISORDERS<br/>[FR] DERIVES CARBOXAMIDE DE PYRROLIDINE, PIPERIDINE ET HEXAHYDROAZEPINE UTILISES DANS LE TRAITEMENT DE TROUBLES THROMBOTIQUES
  申请人：ORTHO PHARMACEUTICAL CORPORATION

  公开号：WO1997041102A1

  公开（公告）日：1997-11-06

  (EN) Carboxamide derivatives of pyrrolidine, piperidine, and hexahydroazepine of formula (I) are disclosed as useful in treating platelet-mediated thrombotic disorders.(FR) L'invention se rapporte à des dérivés carboxamide de pyrrolidine, pipéridine et hexahydroazepine de la formule (I) qui sont utilisés dans le traitement des troubles thrombotiques induits par les plaquettes.

  （中文）公开了式（I）的吡咯烷，哌啶和六氢唑啉的羧酰胺衍生物，用于治疗血小板介导的血栓性疾病。
• Processes for the production of cannabidiol derivatives and intermediates thereof
  申请人：Albany Molecular Research, Inc.

  公开号：EP2578561A1

  公开（公告）日：2013-04-10

  This invention relates to a process for the preparation of a product compound of the formula: wherein: R1 is H, substituted or unsubstituted alkyl, carboxylic ester, or acyl; R2 is H, OH, protected hydroxyl, substituted or unsubstituted alkyl, alkenyl, alkynyl, acyl, aryl, or heteroaryl; R3 is H, substituted or unsubstituted alkyl, carboxylic ester, or acyl; R4 is H, substituted or unsubstituted alkyl, silyl, hetero-substituted or unsubstituted acyl, alkylsulfonyl, arylsulfonyl, alkylphosphoryl, or arylphosphoryl; and R6 is H, substituted or unsubstituted alkyl, silyl, hetero-substituted or unsubstituted acyl, alkylsulfonyl, arylsulfonyl, alkylphosphoryl, or arylphosphoryl.

  本发明涉及一种制备公式化合物的过程：其中：R1为氢，取代或未取代烷基，羧酸酯或酰基；R2为氢，羟基，保护羟基，取代或未取代烷基，烯基，炔基，酰基，芳基或杂环芳基；R3为氢，取代或未取代烷基，羧酸酯或酰基；R4为氢，取代或未取代烷基，硅基，杂原子取代或未取代酰基，烷基磺酰基，芳基磺酰基，烷基磷酰基或芳基磷酰基；R6为氢，取代或未取代烷基，硅基，杂原子取代或未取代酰基，烷基磺酰基，芳基磺酰基，烷基磷酰基或芳基磷酰基。
• Sulfonyl esters of tetrahydrocannabinol and derivatives thereof
  申请人：Albany Molecular Research, Inc.

  公开号：EP2578577A1

  公开（公告）日：2013-04-10

  This invention relates to a compound of the formula: wherein: R1 is H, substituted or unsubstituted alkyl, carboxylic ester, or acyl; R2 is H, OH, protected hydroxyl, substituted or unsubstituted alkyl, alkenyl, alkynyl, acyl, aryl, or heteroaryl; R3 is H, substituted or unsubstituted alkyl, carboxylic ester, or acyl; R8, R9, and R10 are the same or different and independently selected from the group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or halo; and R8 and R9; R8 and R10; or R9 and R10; or R8, R9, and R10 can together result in the formation of a cyclic moiety.

  本发明涉及一种化合物，其结构式为：其中：R1为H、取代或未取代的烷基、羧酸酯或酰基；R2为H、OH、保护的羟基、取代或未取代的烷基、烯基、炔基、酰基、芳基或杂环芳基；R3为H、取代或未取代的烷基、羧酸酯或酰基；R8、R9和R10相同或不同且独立地选自以下组中的一种：H、取代或未取代的烷基、取代或未取代的芳基、取代或未取代的杂环芳基或卤素；且R8和R9、R8和R10、或R9和R10；或R8、R9和R10可以共同形成环状基团。